UT-DOXY.ME
Doxy.me, a free, secure telemedicine solution, stands ready to meet increased demand for a simple, convenient way for healthcare providers to meet with their patients remotely, promising to improve the health care experience during this critical time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200318005165/en/
Most telemedicine software products require a lengthy sales cycle, including training, legal review, and software or hardware to install. The process can take weeks to months to get up and running. Doxy.me was designed to be easy to install and simple to use; there are no downloads or apps to install and patients don't need to create accounts. The process is automated, so providers can start practicing telemedicine quickly, even within minutes. This approach means that Doxy.me is perfectly suited to handle the urgent demand for a telemedicine solution during the coronavirus outbreak.
“We’ve seen our sign-ups skyrocket over the past week, and we expect those numbers to keep doubling every day. We’re thrilled that we are in a position to make a difference in the world through our technology,” said Brandon Welch, Founder, Doxy.me. “We believe everyone should have access to telemedicine, and our focus is on assisting the providers and professionals trying to keep people safe and healthy.”
By incorporating standard clinical workflows such as patient check-in and waiting room into the design of Doxy.me, healthcare providers and their patients experience a familiar and natural visit. All the patient needs to start a telemedicine visit is a web link to the doctor’s Doxy.me room using a standard computer.
“Doxy.me brokers an encrypted peer-to-peer connection between a provider and the patient, meaning our server infrastructure won't become overburdened with high video load usage. This means we can scale indefinitely and can provide a free solution to healthcare providers,” said Dylan Turner, COO, Doxy.me.
“Doxy.me is easy to set up, easy to use, and the pricing option is transparent. This means that my busy private-practice office can triage possible coronavirus cases and see patents who are afraid to come in. I was able to set up and implement a telemedicine option overnight,” said Jessica Baker, Baker Family Medical Associates.
About Doxy.me
Founded by Brandon Welch, MS, PhD, and based in Salt Lake City, Utah and Charleston, South Carolina, Doxy.me is making it easier and more affordable for healthcare providers to care for their patients anywhere, including rural and underserved areas. Doxy.me provides patients with a virtual clinic experience that is strongly reminiscent of the traditional consultative model. The company uses state-of-the-art security and encryption protocols, making Doxy.me compliant with HIPAA, GDPR, PHIPA and HITECH requirements, and works on mobile devices (Safari/Chrome) and most desktop browsers. The company also offers a licensed version of Doxy.me for additional features or custom branding.
For more information about Doxy.me or telemedicine, see Doxy.me .
For more information about COVID-19, see the World Health Organization .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200318005165/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Blind Sailor Takes the Stage at WEF: "HIRO’s CHOICE" Project to Set Sail13.1.2026 05:00:00 CET | Press release
A Solo, Non-Stop Crossing of the Pacific Ocean “Blind Sailor Single-Handed Pacific Crossing Project 2027” is a world-first initiative in which Mitsuhiro Iwamoto, a completely blind Japanese yachtsman (blind sailor) based in San Diego, will attempt a solo, non-stop trans-Pacific crossing in the spring of 2027. Sailing a 28-foot yacht single-handedly, he aims to cross the Pacific Ocean from San Diego on the U.S. West Coast to Amakusa, Kumamoto Prefecture, Japan, without making port. Iwamoto will speak about this project at the World Economic Forum Annual Meeting 2026, to be held in January 2026. Project URL: https://hiros-choice.com/ This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108087321/en/ Hiro Iwamoto / Global Keynote Speaker, First Totally Blind Sailor to Cross the Pacific The message he most wishes to convey at the WEF is the power of choice. He lost his sight at the age of sixteen—a moment when he nearly gave up on
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release
New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom